These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 9815965)
1. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Burrows FJ; Derbyshire EJ; Tazzari PL; Amlot P; Gazdar AF; King SW; Letarte M; Vitetta ES; Thorpe PE Clin Cancer Res; 1995 Dec; 1(12):1623-34. PubMed ID: 9815965 [TBL] [Abstract][Full Text] [Related]
2. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781 [TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Takahashi N; Haba A; Matsuno F; Seon BK Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802 [TBL] [Abstract][Full Text] [Related]
4. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. She X; Matsuno F; Harada N; Tsai H; Seon BK Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611 [TBL] [Abstract][Full Text] [Related]
5. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187 [TBL] [Abstract][Full Text] [Related]
6. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Fonsatti E; Jekunen AP; Kairemo KJ; Coral S; Snellman M; Nicotra MR; Natali PG; Altomonte M; Maio M Clin Cancer Res; 2000 May; 6(5):2037-43. PubMed ID: 10815930 [TBL] [Abstract][Full Text] [Related]
7. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. Korn T; Müller R; Kontermann RE J Immunother; 2004; 27(2):99-106. PubMed ID: 14770081 [TBL] [Abstract][Full Text] [Related]
8. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243 [TBL] [Abstract][Full Text] [Related]
9. Lack of specificity of endoglin expression for tumor blood vessels. Balza E; Castellani P; Zijlstra A; Neri D; Zardi L; Siri A Int J Cancer; 2001 Nov; 94(4):579-85. PubMed ID: 11745447 [TBL] [Abstract][Full Text] [Related]
10. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Nettelbeck DM; Miller DW; Jérôme V; Zuzarte M; Watkins SJ; Hawkins RE; Müller R; Kontermann RE Mol Ther; 2001 Jun; 3(6):882-91. PubMed ID: 11407902 [TBL] [Abstract][Full Text] [Related]
11. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Völkel T; Hölig P; Merdan T; Müller R; Kontermann RE Biochim Biophys Acta; 2004 May; 1663(1-2):158-66. PubMed ID: 15157618 [TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and metastasis marker of human tumors. Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465 [TBL] [Abstract][Full Text] [Related]
14. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Gougos A; St Jacques S; Greaves A; O'Connell PJ; d'Apice AJ; Bühring HJ; Bernabeu C; van Mourik JA; Letarte M Int Immunol; 1992 Jan; 4(1):83-92. PubMed ID: 1371694 [TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Tabata M; Kondo M; Haruta Y; Seon BK Int J Cancer; 1999 Aug; 82(5):737-42. PubMed ID: 10417773 [TBL] [Abstract][Full Text] [Related]
16. Active drug targeting with immunoconjugates to choroidal neovascularization. Yasukawa T; Kimura H; Tabata Y; Miyamoto H; Honda Y; Ikada Y; Ogura Y Curr Eye Res; 2000 Dec; 21(6):952-61. PubMed ID: 11262619 [TBL] [Abstract][Full Text] [Related]
17. Umbilical vein and placental vessels from newborns with hereditary haemorrhagic telangiectasia type 1 genotype are normal despite reduced expression of endoglin. Chan NL; Bourdeau A; Vera S; Abdalla S; Gross M; Wong J; Cymerman U; Paterson AD; Mullen B; Letarte M Placenta; 2004; 25(2-3):208-17. PubMed ID: 14972453 [TBL] [Abstract][Full Text] [Related]
18. Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Wang JM; Kumar S; van Agthoven A; Kumar P; Pye D; Hunter RD Int J Cancer; 1995 Sep; 62(6):791-6. PubMed ID: 7558432 [TBL] [Abstract][Full Text] [Related]
19. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. Bodey B; Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1998; 18(5A):3621-8. PubMed ID: 9858949 [TBL] [Abstract][Full Text] [Related]